Upper Gastrointestinal Tumours Clinical Trial
Official title:
A Phase II Trial Evaluating Irinotecan With 5_fluorouracil Plus Leucovorin in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours
The objective of this study is to assess the efficacy and toxicity of a 2 weekly regimen
containing irinotecan combined with leucovorin-modified 5-fluorouracil in the setting of
relapsed or refractory upper gastrointestinal tumours. Patients with locally advanced or
metastatic adenocarcinoma originating from the oesophagogastric junction, stomach or
pancreas who have previously received chemotherapy and have either failed to respond or who
have relapsed after an initial response will be eligible for treatment in this study.
The response rate, failure-free survival and overall survival of treated patients with the
two different regimes will be evaluated. Toxicity and quality of life will also be monitored
closely.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00220168 -
Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours
|
Phase 4 |